Lupus nephritis

Kidney International

Volumn 52, Issue 2, 1997, Pages 538-558

  Berden, Jo H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lupus nephritis; Proteinuria; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A;

ADULT; CASE REPORT; CLINICAL FEATURE; DIALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0030850910     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.365     Document Type: Review

References (209)

1. SOLEZ K, AXELSEN RA, BENEDIKTISSON H, BURDICK JF, COHEN AH, COLVIN RB, CROKER BP, DROZ D, DUNNIL MS, HALLORAN PF, HÄYRY P, JENETTE JC, KEOWN PA, MARCUSSEN N, MIHATSCH MJ, MOROZUMIK K, MYERS BD, NAST CC, OLSEN S, RACUSON LC, RAMOS EL, ROSEN S, SACHS DH, SALOMON DR, SANFILLIPO F, VERANI R, VON WILLEBRAND E, YAMAGUCHI Y: International standarization of criteria for the histological diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44:411-422, 1993
2. ADLER S, COHEN AH, GLASSOCK RJ: Secondary glomerular diseases, in The Kidney, edited by BRENNER BM, Philadelphia, Saunders, 1996, p 1498
3. CHURG J, BERNSTEIN J, GLASSOCK RJ: Lupus nephritis, in Renal Diseases. Classification and Atlas of Glomerular Diseases, edited by CHURG J, BERNSTEIN J, GLASSOCK RJ, New York, Igaku-Shoin, 1995, p 151
4. KASHGARIAN M: Nephrology Forum: Lupus nephritis: lessons from the path lab. Kidney Int 45:928-938, 1994
5. TAN EM: Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93-149, 1989
6. TER BORG EJ, HORST G, HUMMEL EJ, LIMBURG PC, KALLENBERG CGM: Predictive value of rises in anti-double-stranded DNA antibody levels for disease exacerbations in systemic lupus erythematosus: a long term prospective study. Arthritis Rheum 33:634-643, 1990
7. KALUNIAN KC, PANOSIAN-SAHAKIAN N, EBLING FM, COHEN AH, LOUIE JS, KAINE J, HAHN BH: Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus. Arthritis Rheum 32:513-522, 1989
8. KOFFLER D, AGNELLO V, THOBURN R, KUNKEL HG: SLE, prototype of immune complex nephritis in man. J Exp Med 134:169S-179S, 1971
9. EILAT D: Crossreactions of anti-DNA antibodies and the central dogma of lupus nephritis. Immunol Today 6:123-127, 1985
10. DZIARSKI R: Autoimmunity: Polyclonal activation or antigen induction. Immunol Today 9:340-342, 1988
11. IZUI S, LAMBERT PH, MIESCHER PA: Failure to detect circulating DNA-anti-DNA complexes by four radioimmunological methods in patients with systemic lupus erythematosus. Clin Exp Immunol 30:384-392, 1977
12. LAFER EM, RAUCH J, ANDRZEJEWSKI C JR, MUDD D, FURIE B, SCHWARTZ RS, STOLLAR DB: Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med 153:897-909, 1981
13. FAABER P, RIJKE GPM, VAN DE PUTTE LBA, CAPEL PJA, BERDEN JHM: Crossreactivity of human and murine anti-DNA antibodies with heparan sulphate: the major glycosaminoglycan in glomerular basement membrane. J Clin Invest 77:1824-1830, 1986
14. SABBAGA J, PERES LINE SR, POTOCNJAK P, MADAIO MP: A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, the major non-collagenous protein component of the glomerular basement membrane. Eur J Immunol 19:137-143, 1989
15. FOSTER MH, CIZMAN B, MADAIO MP: Biology of disease. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origin. Lab Invest 69:494-507, 1993
16. JACOB L, VIARD JD, ALLENET B, ANIN MF, SLAMA FBH, VANDERKERCKHOVE J, PRIMO J, MARKOVITS J, JACOB F, BACH JF, LE PECO JB, LOUVARD D: A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. Proc Natl Acad Sci USA 86:4669-4673, 1989
17. TERMAAT RM, BRINKMAN K, VAN GOMPEL F, VAN DE HEUVEL LPWJ, VEERKAMP J, SMEENK RJT, BERDEN JHM: Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J Autoimmun 3:531-545, 1990
18. TERMAAT RM, ASSMANN KJM, VAN SON JPHF, DIJKMAN HBPM, KOENE RAP, BERDEN JHM: Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. Lab Invest 68:164-173, 1993
19. CHAN TM, FRAMPTON G, STAINES NA, HOBBY P, PERRY GJ, CAMERON JS: Different mechanism by which anti-DNA Moabs bind to human endothelial cells and glomerular mesangial cells. Clin Exp Immunol 88:68-74, 1992
20. BRINKMAN K, TERMAAT RM, BERDEN JHM, SMEENK RJT: Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today 11:232-234, 1990
21. KRAMERS C, HYLKEMA NM, VAN BRUGGEN MCJ, VAN DE LAGEMAAT R, DIJKMAN HBPM, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94:568-577, 1994
22. DIAMOND B, KATZ JB, PAUL E, ARANOW C, LUSTGARTEN D, SCHARFF MD: The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol 10:731-757, 1992
23. CARSON DA: The specificity of anti-DNA antibodies in systemic lupus erythematosus. J Immunol 146:1-2, 1991
24. BERDEN JHM: Nucleosomes and lupus nephritis, in Lupus Nephritis, edited by LEWIS EJ, Oxford, Oxford University Press, in press
25. REEVES WH, SATOH M, WANG J, CHOU CH, AJMANI AK: Antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am 20:1-28, 1994
26. BURLINGAME RW, BOEY ML, STARKEBAUM G, RUBIN RL: The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 94:184-192, 1994
27. TAX WJM, KRAMERS C, VAN BRUGGEN MCJ, BERDEN JHM: Apoptosis, nucleosomes, and SLE nephritis. Kidney Int 48:666-673, 1995
28. RUMORE PM, STEINMAN CR: Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 86:69-74, 1990
29. COHEN J: Apoptosis. Immunol Today 14:126-130, 1993
30. SAVILL J, FADOK V, HENSON P, HASLETT C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14:131-136, 1993
31. EMLEN W, NIEBUR J, KADERA R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685-3692, 1994
32. MOUNTZ JD, ZHOU T, WU J, WANG W, SU X, CHENG J: Regulation of apoptosis in immune cells. J Clin Immunol 15:1-16, 1995
33. WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, JENKINS NA, NAGATE S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
34. SINGER GG, CARRERA AC, MARSHAK-ROTHSTEIN A, MARTINEZ AC, ABBAS AK: Apoptosis, Fas and systemic autoimmunity: the MRL/lpr model. Curr Opin Immunol 6:913-920, 1994
35. NAGATA S, SUDA T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995
36. WU J, ZHOU T, ZHANG J, HE J, GAUSE WC, MOUNTZ JD: Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA 91:2344-2348, 1994
37. NISITANI S, TSUBATA T, MURAKAMI M, OKAMOTO M, HONJO T: The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow. J Exp Med 178:1247-1254, 1993
38. STRASSER A, WHITTINGHAM S, VAUX DL, BATH ML, ADAMS JM, CORY S, HARRIS AW: Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and exhibits autoimmune diseases. Proc Natl Acad Sci USA 88:8661-8665, 1991
39. CHENG J, ZHOU T, LIU C, SHAPIRO JP, BRADER MJ, KIEFER MC, BARR PJ, MOUNTZ JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994
40. GOEL N, ULRICH DT, ST CLAIR EW, FLEMING JA, LYNCH DH, SELDIN MF: Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38:1738-1743, 1995
41. KNIPPING E, KRAMMER PH, ONEL KB, LEHMAN TJA, MYSLER E, ELKON K: Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735-1737, 1995
42. ARINGER M, WINTERSBERGER W, STEINER CW, KIENER H, PRESTERL E, JAEGER U, SMOLEN JS, GRANINGER WB: High levels of bcl-2 protein in circulating T lymphocytes but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 37:1423-1430, 1994
43. MARRACK P, HUGO P, MCCORMACK J, KAPPLER J: Death and T cells. Immunol Rev 133:119-129, 1993
44. MERYHEW NL, SHAVER C, MESSNER RP, RUNQUIST OA: Mononuclear phagocyte system dysfunction in murine SLE: abnormal clearance kinetics precede clinical disease. J Lab Clin Med 117:181-193, 1991
45. ROBEY FA, JONES KD, STEINBERG AD: C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 161:1344-1356, 1985
46. ROBEY FA, JONES KD, TANAKA T, LIU TY: Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactivc protein. J Biol Chan 259:7311-7316, 1984
47. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317-1330, 1994
48. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 182:1625-1634, 1995
49. SUENAGA R, ABDOU NI: Anti-(DNA-histone) antibodies in active lupus nephritis. J Rheumatol 23:279-285, 1996
50. BELL DA, MORRISON B, VANDENBYGARRT P: Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 85:1487-1496, 1990
51. MOHAN C, ADAMS S, STANIK V, DATTA SK: Nucleosome, a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177:1367-1381, 1993
52. MAMULA MJ: Lupus autoimmunity: from peptides to particles. Immunol Rev 144:301-314, 1995
53. BERDEN JHM, SMEENK RJT: Nucleosome-specific auto-antibodies, in Autoantibodies, edited by PETER JB, SHOENFELD Y, Amsterdam, Elsevier, 1996, p 574
54. CHABRE H, AMOURA Z, PIETTE JC, GODEAU P, BACH JF, KOUTOUZOV S: Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 38:1485-1491, 1995
55. BURLINGAME RW, RUBIN RL, BALDERAS RS, THEOFILOPOULOS AN: Genesis and evolution of anti-chromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 91:1687-1696, 1993
56. AMOURA Z, CHABRE H, KOUTOUZOV S, LOTTON C, CABRESPINES A, BACH JF, JACOB L: Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 37:1684-1688, 1994
57. MASSA M, DE BENEDETTI F, PIGNATTI P: Anti-double stranded DNA, anti-histone and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 12:219-225, 1994
58. SMEENK RJT, HYLKEMA MN: Detection of antibodies to DNA: a technical assessment. Mol Biol Rep 17:71-79, 1992
59. HYLKEMA MN: Autoimmunity against nucleosomes and lupus nephritis. PhD thesis, University of Amsterdam, Amsterdam, 1995, p 95
60. STEMMER C, RICHALET-SECORDEL P, VAN BRUGGEN MCJ, KRAMERS C, BERDEN JHM, MULLER S: Dual reactivity of several monoclonal anti-nucleosome autoantibodies for double stranded DNA and a short segment of histone H3. J Biol Chem 271:21257-21261, 1996
61. KANWAR YS, LIU ZZ, KASHIHARA N, WALLNER EI: Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 11:390-413, 1991
62. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, BERDEN JHM: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
63. SCHMIEDEKE TMJ, STOCKL FW, WEBER R, SUGISAKI Y, BATSFORD SR, VOGT A: Histories have high affinity for the glomerular basement membrane. J Exp Med 169:1879-1894, 1989
64. TERMAAT RM, ASSMAN KJM, DIJKMAN HBPM, SMEENK RJT, BERDEN JHM: Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 42:1363-1371, 1992
65. RAZ E, BREZIS M, ROSENMANN E, EILAT D: Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 142:3076-3082, 1989
66. DI VALERIO R, BERNSTEIN KA, VARGHESE E, LEFKOWITH JB: Murine lupus glomerulotropic monoclonal antibodies exhibit differing specificites but bind via a common mechanism. J Immunol 155:2258-2268, 1995
67. BERNSTEIN KA, DI VALERIO R, LEFKOWITH JB: Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 154:2424-2433, 1995
68. BERNSTEIN KA, BOLSHOUN D, LEFKOWITH JB: Serum glomerular binding activity is highly correlated with renal disease in MRL/lpr mice. Clin Exp Immunol 93:418-423, 1993
69. BERNSTEIN KA, KAHL LE, BALOW JE, LEFKOWITH JB: Serologic markers of lupus nephritis in patients: use of a tissue based ELISA and evidence for immunopathogenic heterogeneity. Clin Exp Immunol 98:60-65, 1994
70. VAN BRUGGEN MCJ, WALGREEN B, RIJKE GPM, CORSIUS MJAMM, ASSMANN KJM, SMEENK RJT, VAN DEDEM GWK, KRAMERS C, BERDEN JHM: Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 50:1555-1564, 1996
71. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, BERDEN JHM: Monoclonal antibodies against the core protein and the membrane glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan. Characterization and immunohistochemical application in human tissues. J Histochem Cytochem 42:89-102, 1994
72. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMAN KJM, WEENING JJ, BERDEN JHM: Distribution of GBM heparan sulphate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43:454-463, 1993
73. VAN BRUGGEN MCJ, KRAMERS C, HYLKEMA MN, VAN DEN BORN J, BAKKER MAH, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 146:753-763, 1995
74. VAN BRUGGEN MCJ, KRAMERS C, WALGREEN B, ELEMA JD, KALLENBERG CGM, VAN DEN BORN J, ASSMANN KJM, SMEENK RJT, MULLER S, MONESTIER M, BERDEN JHM: Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 12:57-66, 1997
75. STOCKL FW, MULLER S, BATSFORD S, SCHMIEDEKE TMJ, WALDHERR R, ANDRASSY K, SUGISAKI Y, NAKABAYASHI K, NAGASAWA T, RODRIGUEZ-ITURBE B, DONINI U, VOGT A: A role for histones and ubiquitin in lupus nephritis? Clin Nephrol 41:10-17, 1994
76. VAN BRUGGEN MCJ, KRAMERS C, HYLKEMA MN, SMEENK RJT, BERDEN JHM: Significance of anti-nuclear and anti-extracellular matrix auto-antibodies for albuminuria in murine lupus nephritis. A longitudinal study on plasma and glomerular eluates in MRL/lpr mice. Clin Exp Immunol 105:132-139, 1996
77. LAMBERT PH, DIXON FJ, ZUBLER RH, AGNELLO V, CAMBIASO C, CASALI P, CLARK J, COWDERY JS, MCDUFFIE MC, HAY FC, MACLENNAN ICM, MASSON P, MULLER-EBERHARD HJ, PENTINNEN K, SMITH M, TAPPEINER G, THEOFILOPOULOS AN, VERROUST P: A WHO collaborative study for the evaluation of eighteen methods of detecting immune complexes in serum. J Clin Lab Immunol 1:1-15, 1978
78. AGNELLO V, KOFFLER D, EISENBERG JW, WINCHESTER RJ, KUNKEL HG: C1q precipitins in the serum of patients with SLE and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 134:228S-241S, 1971
79. ANTES U, HEINZ H-P, Loos M: Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum 31:457-464, 1988
80. SIEGERT CEH, DAHA MR, HALMA C, VAN DER VOORT EAM, BREEDVELD FC: IgG and IgA autoantibodies against C1q in systemic and renal diseases. Clin Exp Rheumatol 10:19-23, 1992
81. SIEGERT CEH, DAHA MR, SWAAK AJG, VAN DER VOORT EAM, BREEDVELD FC: The relationship between serum titers of autoantibodies against C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 67:204-209, 1993
82. SIEGERT CEH, DAHA MR, WESTEDT ML, VAN DER VOORT EAM, BREEDVELD FC: IgG autoantibodies against C1q are correlated with nephritis, hypocomplementaemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 18:230-234, 1991
83. SIEGERT CEH, DAHA MR, TSENG C, COREMANS IEM, VAN ES LA, BREEDVELD FC: Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:851-856, 1993
84. SIEGERT CEH, DAHA MR, VAN DER VOORT EAM, BREEDVELD FC: IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum 33:1646-1654, 1990
85. COREMANS IEM, SPRONK PE, BOOTSMA H, DAHA MR, VAN DER VOORT EAM, KATER L, BREEDVELD FC, KALLENBERG CGM: Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 26:595-601, 1995
86. UWATOKO S, GAUTHIER J, MANNIK M: Autoantibodies to the collagen-like region of the C1q deposit in glomeruli via C1q in immune deposits. Clin Immunol Immunopathol 61:268-273, 1991
87. LIANG HM, SOCHER SA, LARSON MG, SCHUR PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989
88. HAY E, GORDON C, EMERY P: Assessment of lupus: where are we now? Ann Rheum Dis 52:169-172, 1993
89. PONTICELLI C: Current treatment recommendations for lupus nephritis. Drugs 40:19-30, 1990
90. APPEL GV, VALERI A: The course and treatment of lupus nephritis. Annu Rev Med 45:525-537, 1994
91. SLOAN RP, SCHWARTZ MM, KORBET SM, BOROK RZ, THE LUPUS NEPHRITIS COLLABORATIVE STUDY GROUP: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 7:299-305, 1996
92. BRUNS FJ, ADLER S, FRALEY DS, SEGEL DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114:725-730, 1991
93. REICHERT LJM, HUYSMANS FTHM, ASSMANN KJM, KOENE RAP, WETZELS JFM: Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 121:328-333, 1994
94. FALK RJ, HOGAN SL, MULLER KE, JENETTE C, THE GLOMERULAR DISEASE COLLABORATIVE NETWORK: Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. Ann Intern Med 116:438-445, 1992
95. RADHAKRISHNAN J, KUNIS CL, D'AGATI VD, APPEL GB: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42:147-154, 1994
96. FEUTREN G, QUERIN S, NOEL LH, CHATENOUD L, BEAURAIN G, TRON F, LESAVRE P, BACH JF: Effects of cyclosporin in severe lupus erythematosus. J Pediatr 111:1063-1068, 1987
97. NIELSON EG: Nephrology Forum: Pathogenesis and therapy of interstitial nephritis. Kidney Int 35:1257-1270, 1989
98. BUYSEN JGM, HOUTHOFF HJ, KREDIET RT, ARISZ L: Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 5:94-99, 1990
99. CAMERON JS: What is the role of long-term cytotoxic agents in the treatment of lupus nephritis? J Nephrol 6:172-176, 1993
100. FELSON DT, ANDERSON J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med 311:1528-1533, 1984
101. BALOW JE, AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH TT, KLIPPEL JH, STEINBERG AD, PLOTZ PH, DECKER JL: Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 311:491-495, 1984
102. AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH TT, BALOW JE: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:689-695, 1984
103. AUSTIN HA III, KLIPPEL JH, BALOW JE, RICHE NGH, STEINBERG AD, PLOTZ PH, DECKER JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619, 1986
104. STEINBERG AD, STEINBERG SC: Longterm preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945-950, 1991
105. ESDAILE JM, LEVINTON C, FEDERGREEN W, HAYSLETT JP, KASHGARIAN M: The clinical and renal biopsy predictors of long term outcome in lupus nephritis. Q J Med 72:779-833, 1989
106. PONTICELLI C, ZUCCHELLI P, MORONI G, CAGNOLI L, BANFI G, PASQUALI S: Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 28:263-271, 1987
107. CAMERON JS, TURNER BR, OGG CS, WILLIAMS DG, LESSOF MH, CHANTLER C, LEIBOWITZ S: Systemic lupus with nephritis: a long term study. Q J Med 48:1-24, 1979
108. BOUMPAS DT, AUSTIN HA III, VAUGHAN EM, YARBORO CH, KLIPPEL JH, BALOW JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-339, 1993
109. TROMPETER RS, EVANS PR, BARRATT TM: Gonadal function in boys with steroid responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet 1:1177-1179, 1981
110. DAVISON JM: Pregnancy in renal transplant recipients: clinical perspectives. Contrib Nephrol 37:170-178, 1984
111. MCCUNE WJ, GOLBUS J, ZELDERS W, BOHLKE P, DUNNE R, FOX DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423-1431, 1988
112. HOFFMAN GS, KERR GS, LEAVITT RY, HALLAHAN CW, LEBOVICS RS, TRAVIS WD, ROTTEM M, FAUCI AS: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488-498, 1992
113. KINLEN LJ: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(suppl 1A):44-49, 1985
114. LIEBLING MR, MCLAUGHLIN K, BOONSUE S, KASDIN J, BARNETT EV: Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 9:543-548, 1982
115. BOUMPAS DT, AUSTIN HA III, VAUGHAN EM, KLIPPEL JH, STEINBERG AD, YARBORO CH, BALOW JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745, 1992
116. GLAS-VOS JW, KREDIET RT, WEENING JJ, ARISZ L: Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine. Neth J Med 46:4-14, 1995
117. VAN DEN WALL BAKE AWL, BERDEN JHM, DERKSEN RHWM, GLAS-VOS DE JW, HAGEN EC: Therapy of proliferative lupus glomerulonephritis: a prospective trial in the Netherlands. Neth J Med 45:280-284, 1994
118. JONES VJ, CUMMING RH, BACON PA, EVERS J, FRASER ID, BOTHAMLEY J, TRIBE CR, DAVIS P, HUGHES GRV: Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 192:555-576, 1979
119. LEAKER BR, BECKER GJ, DOWLING, JP, KINCAID-SMITH PS: Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression. Clin Nephrol 25:236-244, 1986
120. WEI N, HUSTON DP, LAWLEY TJ, STEINBERG AD, KLIPPEL JH, HALL RP, BALOW JE, DECKER JL: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1:17-21, 1983
121. DERKSEN RHWM, HENE RJ, KALLENBERG CGM, VALENTIJN RM, KATER L: Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 33:168-177, 1988
122. LEWIS EJ, HUNSICKER LG, SHU-PING LAN MA, ROHDE RD, LACHIN JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326:1373-1378, 1992
123. EULER HH, SCHROEDER JO, ZEUNER RA, TESKE EA: A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. Int J Artif Organs 14:639-646, 1991
124. MADORE F, LAZARUS JM, BRADY HR: Therapeutic plasma exchange in renal diseases (editorial review). J Am Soc Nephrol 7:367-386, 1996
125. BOOTSMA H, SPRONK PE, DERKSEN RHWM, DE BOER G, WOLTERS-DICKE H, HERMANS J, LIMBURG PC, GMELIG-MEYLING FHJ, KATER L, KALLENBERG CGM: Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595-1599, 1995
126. NOSSENT JC: End stage renal disease in patients with systemic lupus erythematosus, in Lupus Nephritis, edited by Lewis EJ, Oxford, Oxford University Press, in press
127. CHEIGH JS, STENZL KH: End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 21:2-8, 1993
128. NOSSENT JC, SWAAK AJG, BERDEN JHM: Systemic lupus erythematosus: Analysis of disease activity in 55 patients with end stage renal failure treated with hemodialysis or continous ambulatory peritoneal dialysis. Am J Med 89:169-174, 1990
129. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEIDAI. A disease activity index for lupus patients. Committee on prognosis studies in SLE. Arthritis Rheum 35:630-640, 1992
130. COPLON N, SIEGEL R, FRIES J: Hemodialysis in end stage renal lupus. Trans Am Soc Artif Org 19:302-308, 1973
131. JARRET MP, SANTHANAN S, DELGRECO F: The clinical course of end-stage renal disease in systemic lupus erythematosus. Arch Intern Med 143:1353-1356, 1983
132. COPLON N, DISKIN CJ, PETERSEN J, SWENSON RS: The long term clinical course of systemic lupus erythematosus in end stage renal disease. N Engl J Med 308:186-190, 1983
133. LEAKER B, FAIRLEY KF, DOWLING J, KINCAID-SMITH P: Lupus nephritis: clinical and pathological correlation. Q J Med 238:163-179, 1987
134. GLADMAN DD, GOLDSMITH CH, UROWITZ MB, BACON P, BOMBARDIER C, ISENBERG D, KALUNIAN KC, LIANG MH, MADDISON P, NIVED O, RICHTER M, SNAITH M, SYMMONS D, ZOMA A: Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 21:1468-1471, 1994
135. NOSSENT JC, SWAAK AJG, BERDEN JHM: Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. Ann Intern Med 114:183-188, 1991
136. BUMGARDNER GL, MAUER SM, ASCHER NL, PAYNE WD, DUNN DL, FRYD DS, SUTHERLAND DER, SIMMONS RL, NAJARIAN JS: Long-term outcome of renal transplantation in patients with systemic lupus erythematosus. Transplant Proc 21:2031-2032, 1989
137. GOSS JA, COLE BR, JENDRISAK MD, MCCULLOUGH CS, SO SKS, WINDUS DW, HANTO DW: Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single center experience and review of the literature. Transplantation 52:805-810, 1991
138. KRISHNAN G, THACKER L, ANGSTAD JD, CAPELLI JP: Multicenter analysis of renal allograft survival in lupus patients. Transplant Proc 23:1755-1756, 1991
139. NYBERG G, BLOHME I, PERSSON H, OLAUSSON M, SVALANDER C: Recurrence of SLE in transplanted kidneys: a follow-up transplant biopsy study. Nephrol Dial Transplant 7:1116-1123, 1992
140. AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH TA, KULLICK ME, KLIPPEL JH, DECKER JL, BALOW JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382-391, 1983
141. LEVEY AS, LAN SMPH, CORWIN HL, KASINATH BS, LACHIN JSD, NEILSON EG, HUNSICKER LG, LEWIS EJ: Progression and remission of renal disease in the lupus nephritis collaborative study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 116:114-123, 1992
142. NOSSENT JC, HENZEN-LOGMANS SC, VROOM TM, BERDEN JHM, SWAAK TJG: Contribution of renal biopsy data in predicting outcome in lupus nephritis. Arthritis Rheum 33:970-977, 1990
143. AUSTIN HA III, BOUMPAS DT, VAUGHAN EM, BALOW JE: High risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620-1628, 1995
144. GOULET JR, MACKENZIE T, LEVINTON C, HAYSLETT JP, CIAMPI A, ESDAILE JM: The long-term prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 20:59-65, 1993
145. APPEL GB, COHEN DJ, PIRANI CL, MELTZER JI, ESTES D: Longterm follow up of patients with lupus nephritis. Am J Med 83:877-885, 1987
146. AUSTIN HA III, BOUMPAS DT, VAUGHAN EM, BALOW JE: Predicting renal outcome in severe lupus nephritis: contributions of clinical and histological data. Kidney Int 45:544-550, 1994
147. VALERI A, RADHAKRISHNAN J, ESTES D, D'AGATI V, KOPELMAN R, PERNIS A, FLIS R, PIRANI C, APPEL GB: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42:71-78, 1994
148. DONADIO JV, HOLLEY KE, FERGUSON RH, ILSTRUP DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151-1155, 1978
149. PETRI M, PEREZ-GUTHANN S, LONGENECKER J, HOCHBERG M: Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91:345-353, 1991
150. BAKIR AA, LEVY PS, DUNEA G: The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 24: 159-171, 1994
151. KRAMERS C, STEMMER C, MONESTIER M, VAN BRUGGEN MCJ, RIJKE GPM, HYLKEMA MN, SMEENK RJT, MULLER S, BERDEN JHM: Specificity of monoclonal anti-nucleosome auto-antibodies derived from lupus mice. J Autoimmunity 9:723-729, 1996
152. LOSMAN MJ, FASY TM, NOVICK KE, MONESTIER M: Monoclonal autoantibodies to subnucleosomes from a MRL/Mp(-)/+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA. J Immunol 148:1561-1569, 1992
153. LOSMAN JA, FASY TM, NOVICK KE, MASSA M, MONESTIER M: Nucleosome-specific antibody from an autoimmune MRL/Mp-lpr/lpr mouse. Arthritis Rheum 36:552-560, 1993
154. EHRENSTEIN M, LONGHURST C, ISENBERG DA: Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 92:39-45, 1993
155. KALIYAPERUMAL A, MOHAN C, WU W, DATTA SK: Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 183:2459-2469, 1996
156. PANKEWYCZ OG, MIGLIORINI P, MADAIO MP: Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol 139:3287-3294, 1987
157. SABBAGA J, PANKEWYCZ OG, LUFFT V, SCHWARTZ RS, MADAIO MP: Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun 3:215-235, 1990
158. VLAHAKOS D, FOSTER MH, UCCI AA, BARRETT KJ, DATTA SK, MADAIO MP: Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 2:1345-1354, 1992
159. KRAMERS C, VAN BRUGGEN MCJ, RIJKE GPM, DIJKMAN HBPM, HYLKEMA MN, CROES HJ, FRANSSEN JAM, ASSMANN K, TAX WJM, SMEENK RJT, BERDEN JHM: In vivo ANA is a fixation artifact. Nucleosome complexed anti-nucleosome antibodies bind to the cell surface and are internalized. J Am Soc Nephrol 7:946-954, 1996
160. KOUTOUZOV S, CABRESPINES A, AMOURA Z, CHABRE H, LOTTON C, BACH JF: Binding of nucleosomes to a cell surface receptor: redistribution and endocytosis in the presence of lupus antibodies. Eur J Immunol 26:472-486, 1996
161. TERMAAT RM, BRINKMAN K, NOSSENT JC, SWAAK AJG, SMEENK RJT, BERDEN JHM: Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations. Clin Exp Immunol 82:268-274, 1990
162. KRAMERS C, TERMAAT RM, TER BORG EJ, VAN BRUGGEN MCJ, KALLENBERG CGM, BERDEN JHM: Higher anti-heparan sulphate reactivity during SLE exacerbations with renal manifestations. A long term prospective analysis. Clin Exp Immunol 93:34-38, 1993
163. OHNISHI K, EBLING FM, MITCHELL B, SING RR, HAHN BH, TSAO BP: Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 6:817-830, 1994
164. FOX DA, MCCUNE WJ: Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 20:265-299, 1994
165. RADHAKRISHNAN J, VALERI A, KUNIS CL, APPEL GB: Use of cyclosporin in lupus nephritis. Contrib Nephrol 114:59-72, 1995
166. BERDEN JHM, FAABER P, ASSMANN KJM, RIJKE GPM: Effects of cyclosporin A on autoimmune disease in MRL/1 and BxSB mice. Scand J Immunol 24:405-412, 1986
167. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE JONG PE: Anti-proteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995
168. EDDY AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994
169. BOHLE A, MUELLER GA, WEHRMANN M, MACKENSEN-HAEN S, XIAO JC: Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies and chronic interstitial nephritides. Kidney Int 49(suppl 54):S2-S9, 1996
170. NAKAYAMA K, NEGISHI I, KUIDA K, SHINKAI Y, LOUIE MC, FIELDS LE, LUCAS PJ, STEWART V, ALT FW, LOH DY: Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 261:1584-1588, 1993
171. VEIS DJ, SORENSON CM, SHUTTER JR, KORSMEYER SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993
172. VAN EDEN W: Heat shock proteins as immunogenetic bacterial antigens with the potential to induce and regulate auto-immune arthritis. Immunology 121:5-12, 1996
173. PUSEY CD, REES AJ, EVANS DJ, PETERS K, LOCKWOOD CM: Plasma-exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757-763, 1991
174. FRAMPTON G, HICKS JA, CAMERON JS: Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 39:1225-1231, 1991
175. PIETTE JC, CACOUB P, WECHSLER B: Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum 23:357-366, 1994
176. HUGHSON MD, NADASDY T, MCCARTHY GA, SHOLER C, MIN KW, SILVA F: Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis 20:150-158, 1992
177. ASHERON RA: The catastrophic anti-phospholipid syndrome (editorial). J Rheumatol 19:508-512, 1992
178. CHEIGH JS, KIM H, STENZEL KH, TAPIA L, SULLIVAN JF, STUBENBORD RR, RIGGIO RR, RUBIN AL: Systemic lupus erythematosus in patients with end-stage renal disease: Long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 16:189-195, 1990
179. LUQMANI RA, PALMER RG, BACON PA: Azathioprine, cyclophosphamide and chlorambucil. Baillieres Clin Rheumatol 4:595-619, 1990
180. ALLISON AC, EUGUI E: immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5-28, 1993
181. THOMSON AW, STARZL T: New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 136:71-98, 1993
182. COMA D, ZOJA C, FACCHINITI D, MORIGI M, REMUZZI G: Mycophenolate mofetil prolongs life survival in murine lupus autoimmune disease (abstract). J Am Soc Nephrol 6:825, 1995
183. WARNER LM, ADAMS LM, SEHGAL SN: Rapamycin prolongs survival and arrests pathophysiological changes in murine systemic lupus erythematosus (abstract). Arthritis Rheum 37:289-297, 1994
184. TAKABAYASHI K, KOIKE T, KURASAWA K, MATSUMURA R, SATO T, TOMIOKA H, ITO I, YOSHIKI T, YOSHIDA S: Effect of FK506, a novel immunosuppressive drug on murine systemic lupus erythematosus (abstract). Clin Immunol Immunopathol 51:110-117, 1989
185. KIMATA H, YOSHIDA A, ISHIOKA C, MIKAWA H: Erythropoietin enhances immunoglobin production and proliferation by human plasma cells in a serum-free medium. Clin Immunol Immunopathol 59:495-501, 1991
186. SENNSAEL JJ, VAN DER NIEPEN P, VERBEELEN DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40:121-128, 1991
187. HEBERT LA, BIRMINGHAM DJ, SHEN XP, BRANDT JT, SEDMAK DD, DILLON DJ: Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus. Am J Kidney Dis 24:25-32, 1994
188. PARKE AL: Pregnancy and systemic lupus erythematosus, in Systemic Lupus Erythematosus, edited by LAHITA RG, New York, Churchill Livingstone, 1992, p 543
189. SWAAK AJG, AARDEN LA, STATIUS VAN EPS LW, FELTKAMP TEW: Anti-dsDNA and complement profiles as prognostic guides in SLE. Arthritis Rheum 22:226-235, 1979
190. SWAAK AJG, GROENWOLD J, AARDEN LA, FELTKAMP TEW: Detection of anti-dsDNA as diagnostic tool. Ann Rheum Dis 40:45-49, 1981
191. SWAAK AJG, GROENWOLD J, AARDEN LA, STATIUS VAN EPS LW, FELTKAMP TEW: Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis 41:388-395, 1982
192. SWAAK AJG, GROENWOLD J, BRONSVELD W: Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359-366, 1986
193. MILLER MH, UROWITZ MB, GLADMAN DD, KILLINGER DW: Systemic lupus erythematosus in males. Medicine 62:327-334, 1983
194. KAUFMANN LD, GOMEZ-REINO JJ, HEINICKE MH, GOREVIC PD: Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Am J Kidney Dis 18:189-197, 1989
195. GRUNKE M, LORENZ H-M, HIERONYMUS T, HERRMANN M, GEILER T, HEYDER P, MANGER B, KALDEN JR: Altered in vitro apoptosis and expression of apoptosis-related molecules in SLE lymphocytes are phenomena not specific for SLE (abstract). Arthritis Rheum 39(suppl 9):S142, 1996
196. HERRMANN M, ZOLLER OM, HAGENHOFER M, VOLL R, KALDEN JR: Macrophages from SLE patients have a reduced capacity to engulf apoptotic cells (abstract). Arthritis Rheum 39(suppl 9):S143, 1996
197. SAVILL J: The innate immune system: recognition of apoptotic cells, in Apoptosis and the Immune Response, edited by GREGORY CD, New York, Wiley-Liss, 1995, p 341
198. FOURNIÉ GJ: Detection of nucleosome-IgG immune complexes in ascites from mice transplanted with anti-DNA antibody-screening hybridomas and in plasmas from MRL-lpr/lpr mice. Clin Exp Immunol 104:236-240, 1996
199. JORDAN SC: Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 53:8164-5169, 1989
200. SANY J: Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 6:305-310, 1994
201. RIVERA M, MARCEN R, PASCUAL J, NAYA MT, OROFINO L, ORTUNO J: Kidney transplantation in systemic lupus erythematosus nephritis: a one-center experience. Nephron 56:148-151, 1990
202. GIMOVSKY ML, BENNER P, MONTORO M, PLATT DL, BERNE T, PAUL RH: Successful pregnancy in a patient with systemic lupus erythematosus, renal transplantation and chronic renal failure. A case report. J Reprod Med 28:677-680, 1983
203. GRIEM P, PANTHEL K, KALBACHER H, GLEICHMANN E: Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Eur J Immunol 26:279-287, 1996
204. ATEN J, PRIGENT P, PONCET P, BLANPIED C, CLAESSEN N, DRUET PH, HIRSCH F: Mercuric chloride-induced programmed cell death of a murine T cell hybridoma. Cell Immunol 161:98-106, 1995
205. BOUMPAS DT, AUSTIN HA III, FESSLER BJ, BALOW JE, KLIPPEL JH, LOCKSHIN MD: Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 122:940-950, 1995
206. CIRUELO E, DE LA CRUZ J, LOPEZ I, GOMEZ-REINO JJ: Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 39:2028-2034, 1996
207. MORONI G, BANFI G, PONTICELLI C: Clinical status of patients after 10 years of lupus nephritis. Q J Med 84:681-689, 1992
208. MEJIA G, ZIMMERMAN SW, GLASS NR, MILLER DT, SOLLINGER HW, BELZER FO: Renal transplantation in patients with systemic lupus erythematosus. Arch Intern Med 143:2089-2092, 1983
209. BUMGARDNER GL, MAUER SM, PAYNE WD, DUNN DL, SUTHERLAND DER, FRYD DS, ASCHER NL, SIMMONS RL, NAJARIAN JS: Single center 1-15 years results of renal transplantation in patients with systemic lupus erythematosus. Transplantation 46:703-709, 1988